Next-generation sequencing reveals a controlled immune response to Zaire Ebola virus challenge in cynomolgus macaques immunized with vesicular stomatitis virus expressing Zaire Ebola virus glycoprotein (VSVΔG/EBOVgp)

Clin Vaccine Immunol. 2015 Mar;22(3):354-6. doi: 10.1128/CVI.00733-14. Epub 2015 Jan 14.


Vesicular stomatitis virus expressing Zaire Ebola virus (EBOV) glycoprotein (VSVΔG/EBOVgp) could be used as a vaccine to meet the 2014 Ebola virus outbreak. To characterize the host response to this vaccine, we used mRNA sequencing to analyze peripheral blood mononuclear cells (PBMCs) from cynomolgus macaques after VSVΔG/EBOVgp immunization and subsequent EBOV challenge. We found a controlled transcriptional response that transitioned to immune regulation as the EBOV was cleared. This observation supports the safety of the vaccine.

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Democratic Republic of the Congo
  • Ebola Vaccines / immunology*
  • Ebolavirus / genetics
  • Ebolavirus / immunology*
  • Ebolavirus / pathogenicity
  • Gene Expression
  • Hemorrhagic Fever, Ebola / immunology*
  • High-Throughput Nucleotide Sequencing
  • Leukocytes, Mononuclear / immunology*
  • Leukocytes, Mononuclear / metabolism
  • Macaca fascicularis
  • Sequence Analysis, RNA
  • Time Factors
  • Transcriptome
  • Vaccines, Synthetic / immunology
  • Vesiculovirus / immunology*
  • Viral Envelope Proteins / immunology*


  • Antibodies, Viral
  • Ebola Vaccines
  • Vaccines, Synthetic
  • Viral Envelope Proteins
  • envelope glycoprotein, Ebola virus